<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Allelic loss at chromosome 9q31-34 is a frequent event in many lymphoproliferative <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we examined DBC1 at 9q33.1 as a potential target in <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>DBC1 is a putative <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor that has been shown to be involved in the regulation of cell growth and programmed cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The methylation status of the DBC1 promoter CpG island was examined by methylation-specific PCR, <z:chebi fb="0" ids="17137">bisulfite</z:chebi> sequencing, and methylation-specific melting curve analysis </plain></SENT>
<SENT sid="4" pm="."><plain>DBC1 was hypermethylated in 5 of 5 B-cell-derived <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines, 41 of 42 diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 24 of 24 follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 5 of 5 mantle cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 4 of 4 small lymphocytic <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 1 of 2 lymphoplasmacytoid <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, and in 12 of 12 <z:hpo ids='HP_0006721'>acute lymphoblastic leukemias</z:hpo>, but was unmethylated in 1 case of splenic marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, in 12 of 12 <z:hpo ids='HP_0006775'>multiple myelomas</z:hpo>, in 24 of 24 reactive lymph nodes, and in 12 of 12 samples of blood lymphocytes from random donors </plain></SENT>
<SENT sid="5" pm="."><plain>DBC1 hypermethylation was associated with transcriptional silencing in <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines, and reexpression of this gene could be induced by treatment with the demethylating agent, <z:chebi fb="0" ids="50131">5-aza-2'-deoxycytidine</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Our data suggest that hypermethylation of the DBC1 promoter region is a frequent event during the development of lymphoproliferative <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, and that DBC1 hypermethylation may serve as a marker for these <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
</text></document>